Zonisamide: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Epilepsy

Drugs

Volumn 45, Issue 5, 1993, Pages 760-787

  Peters, David H ^a   Sorkin, Eugene M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; ETHOSUXIMIDE; ETHOTOIN; METHARBITAL; NITRAZEPAM; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; SULTIAME; TRIMETHADIONE; VALPROIC ACID; ZONISAMIDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOREXIA; ANTICONVULSANT ACTIVITY; ATAXIA; CHILD; CONTROLLED STUDY; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTERACTION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG TOLERANCE; EPILEPSY; FOCAL EPILEPSY; GRAND MAL EPILEPSY; HUMAN; HUMAN EXPERIMENT; INFANT; INTRAVENOUS DRUG ADMINISTRATION; LENNOX GASTAUT SYNDROME; MAJOR CLINICAL STUDY; MENTAL PERFORMANCE; MOUSE; NEPHROLITHIASIS; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRESCHOOL CHILD; PRIORITY JOURNAL; RAT; REVIEW; SCHOOL CHILD;

ANIMAL; ANTICONVULSANTS; CLINICAL TRIALS; COMPARATIVE STUDY; EPILEPSY; HUMAN; ISOXAZOLES;

EID: 0027314348     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199345050-00010     Document Type: Article

References (104)

1. Voltage-dependent current of vertebrate neurons and their role in membrane excitability
2. Do anticonvulsants have a teratogenic effect?
3. Reserpine-induced alterations in brain amines and their relationship to changes in the incidence of minimal electroshock seizures in mice
4. Treatment of two hundred disturbed psychotics with reserpine
5. The genetic animal model of reflex epilepsy in the Mongolian gerbil: differential efficacy of new anticonvulsive drugs and prototype antiepileptics
6. Zonisamide (CI-912) and cognition: results from preliminary study
7. Determination of zonisamide (3-sulphamoylmethyl-1,2-benzisoxazole) in plasma at therapeutic concentrations by high performance liquid chromatography
8. Drug interactions of zonisamide (CI-912) with phenytoin and carbamazepine. Abstract
9. A facilitation action of reserpine on the central nervous system
10. Proposal for revised clinical and electroencephalographic classification of epileptic seizures
11. Blood-brain barrier transport of CI-912: single passage equilibration of erythrocyte-borne drug
12. Neurological diseases: seizure disorders
13. Effect of zonisamide (CI-912) on a synaptic system model
14. Study of zonisamide, a new antiepileptic drug in refractory epilepsy (in Japanese)
15. Antiepileptic medications in development
16. Anticonvulsant effects of zonisamide on amygdaloid kindling in rats
17. Neuropharmacology of zonisamide, a new antiepileptic drug
18. A clinical evaluation of zonisamide (ZNS, AD-810) on partial epilepsy (in Japanese)
19. Zonisamide
20. Clinical experience of zonisamide (AD-810), a new antiepileptic drug for refractory epilepsy (in Japanese)
21. General pharmacology of the novel antiepileptic compound zonisamide — 1st communication: effects on the central nervous system
22. Differential antagonism of denzinol to various components of metrazol-induced seizures in rats and mice
23. Effects of zonisamide (AD-810) on refractory epilepsy in children: special reference to temporal lobe abnormalities
24. Long term efficacy and safety of zonisamide in treatment of epilepsy (in Japanese)
25. Effects of zonisamide (AD-810) on tungstic acid gel-induced thalamic generalised seizures and conjugated estrogen-induced cortical spike-wave discharges in cats
26. 3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug; electroencephalographic profile
27. Y, Shimizu M, et al. Pharmacokinetic studies of AD-810, a new antiepileptic compound
28. HPLC analysis of antiepileptic drugs in blood samples: microbore separation of fourteen compounds
29. Simultaneous determination of zonisamide and nine other antiepileptic drugs and metabolites in serum. A comparison of microbore and conventional high-performance liquid chromatography
30. Competitive binding enzyme immunoassay for zonisamide, a new antiepileptic drug, with selected paired-enzyme labelled antigen and antibody
31. Treatment of epilepsy with zonisamide (ZNA), a new antiepileptic drug (in Japanese)
32. An experimental study on the modes of appearance and disappearance of suppressive effect of antiepileptic drugs on kindled seizure
33. Effects of 3-sulfamoylmethyl-1,2-benzisoxazole (AD-810) and some antiepileptics on the kindled seizures in the neocortex, hippocampus and amygdala in rats
34. A clinical trial of zonisamide (ZNA), a new antiepileptic drug on adults and children with refractory epilepsy (in Japanese)
35. Factors influencing serum concentration of zonisamide in epileptic patients
36. The long term treatment of zonisamide for epileptic patients with intractable epilepsy (in Japanese)
37. Monotherapy for childhood epilepsies with zonisamide
38. Zonisamide in myoclonic epilepsy: a case report
39. Intractable myoclonic seizures treated with zonisamide
40. Efficacy and safety of zonisamide: results of a multicenter study
41. Seizures induced or aggravated by anticonvulsants
42. Determination of serum zonisamide concentration by the use of enzyme immunoassay technique
43. 3-Sulphamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Pharmacological profile
44. Pharmacokinetic and pharmacodynamic tolerance of a new anticonvulsant agent (3-sulphamoylmethyl-1,2-benzisoxazole) compared to phenobarbitone, diphenylhydantoin and carbamazepine in rats
45. Binding of sulfonamides to erythrocyte proteins and possible drug-drug interaction
46. Binding of sulfonamides to erythrocytes and their components
47. 14C]methyl)-1,2-benzisoxazole (AD-810) in rats, dogs and monkeys and of AD-810 in men
48. Multiple actions of phenytoin on mouse spinal cord neurones in cell culture
49. Relation of laboratory evaluation to clinical effectiveness of antiepileptic drugs
50. 3H]Zonisamide binding in rat brain
51. Therapeutic efficacy and blood concentrations of zonisamide (AD-810) in epileptic children (in Japanese)
52. A clinical phase II study of a new antiepileptic, zonisamide (AD-810) in refractory seizures (in Japanese)
53. Monitoring plasma concentrations of zonisamide and clonazepam in an epileptic attempting suicide by an overdose of the drugs
54. General pharmacology of the novel antiepileptic compound zonisamide — 2nd communication: effects on cardiovascular, visceral, renal and blood functions
55. Pharmacokinetics of zonisamide: sataurable distribution into human and rat erythrocytes and into rat brain
56. Use of a new antiepileptic drug, AD-810 (zonisamide, ZNS) — long term treatment of intractable epilepsy patients (in Japanese)
57. Simultaneous HPLC determination of zonisamide and other antiepileptic drugs in human serum (in Japanese)
58. Treatment of epilepsy with a new antiepileptic drug zonisamide (phase III study) — single agent therapy and multiple drug therapy (in Japanese)
59. Treatment of refractory paediatric epilepsy with zonisamide (AD-810) [in Japanese]
60. Phase III study of AD-810 [zonisamide (ZNS)], a new antiepileptic, in the treatment of paediatric epilepsy (in Japanese)
61. Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy
62. Clinical experience of zonisamide (ZNS), treatment of paediatric epilepsy (in Japanese)
63. Clinical experience of zonisamide (AD-810) on refractory epilepsy (in Japanese)
64. Clinical efficacy and safety of a new antiepileptic drug, zonisamide — a multi-institutional phase III study (in Japanese)
65. Therapeutic effect of zonisamide (AQ-810, ZNS), on refractory epilepsy (in Japanese)
66. Single drug or combination therapy for epilepsy
67. Serum anticonvulsant concentrations in epileptic patients with mental symptoms — a preliminary report
68. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD-810, CI 912), a novel anticonvulsant
69. Pilot study of zonisamide (1,2-Benzisoxazole-3-methanesulphonamide) in patients with refractory partial seizures
70. Clinical experience with zonisamide (AD-810, ZNA), a new antiepileptic in refractory seizures (in Japanese)
71. Zonisamide enhances slow sodium inactivation in Myxicola
72. Influence of phenobarbital, cimetidine, and renal disease on zonisamide kinetics
73. Zonisamide
74. Efficacy evaluation of AD-810 (zonisamide) — results of a double-blind comparison with carbamazepine (CBZ) [in Japanese]
75. Myoclonic, atonic and absence seizures following institution of carbamazepine therapy in children
76. Effects and side effects of zonisamide during long term medication
77. The antiepileptic effect of zonisamide in patients with refractory seizures
78. The antiepileptic effect of zonisamide on patients with refractory seizures and its side effect
79. Epidemiology, classification, natural history and genetics of epilepsy
80. Efficacy of zonisamide in children with refractory partial seizures
81. Effect of food on the oral absorption of zonisamide in normal healthy volunteers
82. Exacerbation of seizures in children by carbamazepine
83. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex
84. Treatment of paediatric epilepsy with AD-810 (zonisamide — ZNS) [in Japanese]
85. Treatment of paediatric epilepsy with AD-810 (zonisamide-ZNS) — efficacy of treatment and blood levels (in Japanese)
86. Efficacy of zonisamide for intractable epilepsy in childhood
87. Treatment of intractable epilepsy with a new antiepileptic drug, zonisamide (AD-810), with special reference to dosage reduction of concurrent drugs (in Japanese)
88. Zonisamide (AD-810, CI-912)
89. Phenytoin block of low threshold calcium channels is voltage- and frequency dependent. Abstract
90. Zonisamide (AD-810, ZNS) in epilepsy therapy (in Japanese)
91. Studies on 3-substituted 1,2 benzisoxazole derivatives. Syntheses of 3-(sufamoylmethyl)-1,2-benzisoxazole derivatives and their anticonvulsant activities
92. Syntheses of 2-sulfamoylmethylbenzoxazole derivatives and determination of their anticonvulsant activities
93. Anticonvulsant activity of zonisamide and phenytoin on seizure activity of the feline visual cortex
94. Effect of a novel anticonvulsant, zonisamide (AD-810, CI-912), in an experimental model of photosensitive epilepsy
95. Nonlinear pharmacokinetics of CI-912 in adult epileptic patients
96. Zonisamide in epilepsy: a pilot study
97. Methodological requirements for clinical trials in refractory epilepsies — our experience with zonisamide
98. Open clinical trial of a new antiepileptic drug, zonisamide (ZNA) on 49 patients with refractory epileptic seizures (in Japanese)